Paradromics

Paradromics recorded from its Connexus BCI in a human during a 20-minute procedure, widening the race.

The first participant implanted with Paradromics' Connexus BCI — a Michigan woman in her sixties with a progressive motor neuron disease — used it for unscripted, real-time speech and text. The distinction from earlier speech neuroprostheses is what she was doing: not copying researcher-selected phrases but choosing her own words, answering open questions, and talking to her grandchildren on a live phone call. Paradromics also reports separating neural signatures for attempted speech, where the person tries to produce sound, from imagined speech, where language is generated internally without any attempt — two different control signals from one implant. This is one participant in an FDA-IDE early feasibility study, and accuracy, vocabulary and durability figures have not been published.

The FDA cleared Paradromics to widen its Connect-One early feasibility study so participants with the Connexus implant can drive a broader range of ordinary personal devices — phones, tablets and computers — through the Convey interface, rather than only the lab-controlled setup the study started with. It is a study-protocol expansion, not a marketing approval: Connexus remains investigational, and the number of implanted participants is still small. The significance is what an implant is being allowed to control, moving from cursor-and-keyboard demonstrations toward the devices patients actually use.